AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 616930567 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine-based standard chemotherapy
Number of subjects: 62
Study 34124972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for insomnia and pain (CBTi.p., N = 18)
Number of subjects: 35
Study 34124972 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (N = 17)
Number of subjects: 35
Study 33006763 — intervention group
Group type: EXPERIMENTAL
Intervention: Video‐based PA counseling intervention (Video-PA)
Number of subjects: 59
Study 33006763 — intervention group
Group type: COMPARATOR
Intervention: Active control (Video-C)
Number of subjects: 59
Study 36054143 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (800 mg/day for four days)
Number of subjects: 38
Study 33844014 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure Variability (SBPV)
Number of subjects: 1394
Study 33844014 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure Variability (PPV)
Number of subjects: 1394
Study 33844014 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure Variability (DBPV)
Number of subjects: 1394
Study 33844014 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Arterial Pressure Variability (MAPV)
Number of subjects: 1394
Study 33028084 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant sunitinib (50 mg/day; 4 weeks on/2 weeks off)
Number of subjects: 609
Study 33028084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study 33041039 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL of 1:1 fish:flaxseed oil blend
Number of subjects: 180
Study 33041039 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL of 1:1 fish:flaxseed oil blend with 200 mg of α‐tocopherol
Number of subjects: 180
Study 33041039 — intervention group
Group type: COMPARATOR
Intervention: No supplement added to colostrum (control)
Number of subjects: 180
Study 33041039 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 180
Study 35302412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral decubitus position (LP group)
Number of subjects: 90
Study 35302412 — intervention group
Group type: COMPARATOR
Intervention: Supine position (SP group)
Number of subjects: 90
Study 35302412 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LP and SP)
Number of subjects: 90
Study 34607865 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 451
Study 32384578 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% RX0041-002
Number of subjects: 648
Study 32384578 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% RX0041-002
Number of subjects: 648
Study 32384578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 648
Study 33954891 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention for increasing physical activity and decreasing sedentary time
Number of subjects: 85
Study 33954891 — intervention group
Group type: COMPARATOR
Intervention: Behavior 'as usual' wait-listed control
Number of subjects: 85
Study 33741237 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane (test group; n = 25)
Number of subjects: 50
Study 33741237 — intervention group
Group type: COMPARATOR
Intervention: Split-thickness skin graft (control group; n = 25)
Number of subjects: 50
Study 33741237 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane (test group)
Number of subjects: 50
Study 33741237 — intervention group
Group type: COMPARATOR
Intervention: Split-thickness skin graft (control group)
Number of subjects: 50
Study 35968361 — intervention group
Group type: EXPERIMENTAL
Intervention: CX-DZ-II intelligent electronic stimulator
Number of subjects: 164
Study 35968361 — intervention group
Group type: COMPARATOR
Intervention: SDZ-II regular electronic stimulator
Number of subjects: 164
Study 33393104 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot care protocol
Number of subjects: 57
Study 35778935 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan dressing
Number of subjects: 25
Study 35778935 — intervention group
Group type: COMPARATOR
Intervention: Nanosilver dressing
Number of subjects: 25
Study 34613358 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin and steroids
Number of subjects: 0
Study 34613358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32229443 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g/day flaxseed flour with meals (n=60)
Number of subjects: 90
Study 32229443 — intervention group
Group type: COMPARATOR
Intervention: 15 mL/day of a lactulose solution on an empty stomach (n=30)
Number of subjects: 90
Study 35168620 — intervention group
Group type: EXPERIMENTAL
Intervention: Talonavicular joint mobilization (TJM)
Number of subjects: 48
Study 35168620 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended intervention
Number of subjects: 48
Study 32791641 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulse-radio ultra-wideband (IR-UWB) radar technology
Number of subjects: 79
Study 32791641 — intervention group
Group type: COMPARATOR
Intervention: Micromovement sensitive mattress (MSM) and IR-UWB
Number of subjects: 79
Study 35765085 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied allogeneic cellular product containing CD362 enriched mesenchymal stem cells suspended in a collagen solution
Number of subjects: 2
Study 33315763 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab (high-affinity anti-IL-6 antibody)
Number of subjects: 0
Study 33315763 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 0
Study 33315763 — intervention group
Group type: EXPERIMENTAL
Intervention: CD38 antibodies
Number of subjects: 0
Study 33077559 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) dressing, n=224
Number of subjects: 448
Study 33077559 — intervention group
Group type: COMPARATOR
Intervention: Non-NPWT dressing, n=224
Number of subjects: 448
Study 35912152 — intervention group
Group type: EXPERIMENTAL
Intervention: Postauricular injection of methylprednisolone sodium succinate
Number of subjects: 60
Study 35912152 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 60
Study 33226000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention-guided strategy plus optimal medical therapy (OMT)
Number of subjects: 251
Study 33226000 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 251
Study 33226000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention-guided strategy plus OMT
Number of subjects: 251
Study 32912323 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic assisted feedback (22 homes, 69 care units)
Number of subjects: 8766
Study 32912323 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced assisted feedback 2 (23 homes, 72 care units)
Number of subjects: 8766
Study 32912323 — intervention group
Group type: COMPARATOR
Intervention: Simple feedback (control group)
Number of subjects: 8766
Study 35297385 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate administration in the French dataset (1234 patients, 450 matched)
Number of subjects: 54787
Study 35297385 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate administration in the North-American dataset (4902 patients, 1238 matched)
Number of subjects: 54787
Study 35730613 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight-loss intervention
Number of subjects: 121
Study 35730613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal butyrate increase
Number of subjects: 121
Study 32217792 — intervention group
Group type: EXPERIMENTAL
Intervention: US-MR image fusion navigation
Number of subjects: 20
Study 32217792 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy
Number of subjects: 20
Study 34983199 — intervention group
Group type: EXPERIMENTAL
Intervention: Employer EBI implementation
Number of subjects: 63
Study 33667721 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy and Ready to Learn (HRL) status
Number of subjects: 7565
Study 33667721 — intervention group
Group type: COMPARATOR
Intervention: Sociodemographic factors
Number of subjects: 7565
Study 33667721 — intervention group
Group type: COMPARATOR
Intervention: Health, family, and neighborhood factors
Number of subjects: 7565
Study 33667721 — intervention group
Group type: COMPARATOR
Intervention: State-level HRL prevalence
Number of subjects: 7565
Study 32585585 — intervention group
Group type: EXPERIMENTAL
Intervention: drinks/week
Number of subjects: 1500000
Study 32585585 — intervention group
Group type: EXPERIMENTAL
Intervention: alcohol use disorder (AUD)
Number of subjects: 1500000
Study 32585585 — intervention group
Group type: EXPERIMENTAL
Intervention: age-adjusted alcohol use disorder identification test (AUDIT-C)
Number of subjects: 1500000
Study 34269634 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-facilitated PADs
Number of subjects: 72
Study 34269634 — intervention group
Group type: COMPARATOR
Intervention: Non-peer clinician-facilitated PADs
Number of subjects: 72
Study 34848523 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol cypionate intramuscular (IM) and micronised progesterone oral (PO), in addition to standard of care (SOC)
Number of subjects: 120
Study 34848523 — intervention group
Group type: COMPARATOR
Intervention: Placebo, in addition to standard of care (SOC)
Number of subjects: 120
Study 34856196 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neural ulcerative colitis (DNUC) system for real-time histological assessment
Number of subjects: 770
Study 34856196 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neural ulcerative colitis (DNUC) for endoscopic scoring
Number of subjects: 770
Study 33824248 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphenyl dimethyl dicarboxylate/ursodeoxycholic acid
Number of subjects: 33
Study 33824248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 35059786 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet (8%) + 600 mg kg-1 curcumin
Number of subjects: 36
Study 35059786 — intervention group
Group type: COMPARATOR
Intervention: Normal protein diet (19%)
Number of subjects: 36
Study 35059786 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (8%)
Number of subjects: 36
Study 32465257 — intervention group
Group type: EXPERIMENTAL
Intervention: Era 2 (October 2018 - June 2019)
Number of subjects: 25820
Study 32465257 — intervention group
Group type: COMPARATOR
Intervention: Era 1 (January 2006 - September 2018)
Number of subjects: 25820
Study 34288114 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line ASCT (n = 20)
Number of subjects: 76
Study 34288114 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line ASCT (n = 48, following BEAM)
Number of subjects: 76
Study 34288114 — intervention group
Group type: EXPERIMENTAL
Intervention: Third/fourth-line ASCT (n = 8)
Number of subjects: 76
Study 34288114 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line ASCT with low-risk FLIPI at relapse
Number of subjects: 76
Study 34288114 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line ASCT with intermediate-risk FLIPI at relapse
Number of subjects: 76
Study 34288114 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line ASCT with high-risk FLIPI at relapse
Number of subjects: 76
Study 33272365 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides (per 10 mg/dl)
Number of subjects: 6901
Study 33272365 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HDL-C (per 10 mg/dl)
Number of subjects: 6901
Study 33272365 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant-C (per 10 mg/dl)
Number of subjects: 6901
Study 33272365 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherogenic dyslipidemia (triglycerides >150 mg/dl and HDL-C <40 mg/dl in men or <50 mg/dl in women)
Number of subjects: 6901
Study 33272365 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant-C ≥30 mg/dl
Number of subjects: 6901
Study 35102669 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychromatic short-wavelength-enriched light
Number of subjects: 12
Study 35102669 — intervention group
Group type: COMPARATOR
Intervention: Dim, red ambient light (control)
Number of subjects: 12
Study 33049701 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 45
Study 32634068 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 90
Study 32634068 — intervention group
Group type: COMPARATOR
Intervention: Oral chemotherapy
Number of subjects: 90
Study 35671067 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic Oxygenated Perfusion (HOPE)
Number of subjects: 110
Study 35671067 — intervention group
Group type: COMPARATOR
Intervention: Static Cold Storage (SCS)
Number of subjects: 110
Study 34388615 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual disaster simulation
Number of subjects: 0
Study 34388615 — intervention group
Group type: COMPARATOR
Intervention: Live disaster simulation
Number of subjects: 0
Study 35373585 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (125 mg, twice per day for 3 days)
Number of subjects: 32
Study 35373585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 33109706 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 0
Study 33109706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33109706 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Edaravone arm
Number of subjects: 0
Study 33100818 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostatic Precipitation (EP) during laparoscopic hysterectomy
Number of subjects: 35
Study 33100818 — intervention group
Group type: COMPARATOR
Intervention: No Electrostatic Precipitation (No EP) during laparoscopic hysterectomy
Number of subjects: 35
Study 33100818 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostatic Precipitation (EP)
Number of subjects: 35
Study 33100818 — intervention group
Group type: COMPARATOR
Intervention: No Electrostatic Precipitation (No EP)
Number of subjects: 35
Study 34986562 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochar amendment at 1%
Number of subjects: 3
Study 34986562 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochar amendment at 3%
Number of subjects: 3
Study 34986562 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead toxicity at 400 mg kg‐1
Number of subjects: 3
Study 34986562 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead toxicity at 1200 mg kg‐1
Number of subjects: 3
Study 34986562 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg kg‐1 lead)
Number of subjects: 3
Study 32831969 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversational therapy through VR
Number of subjects: 36
Study 32831969 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 36
Study 33784196 — intervention group
Group type: EXPERIMENTAL
Intervention: Control-IQ technology
Number of subjects: 9451
Study 34081197 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic‐assisted latissimus dorsi transfer alone
Number of subjects: 15
Study 34081197 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic‐assisted latissimus dorsi transfer with partial cuff repair
Number of subjects: 15
Study 33900918 — intervention group
Group type: COMPARATOR
Intervention: 3D Convolutional Neural Network (CNN) using effective connectivity (EC) matrices from EEG recordings of AUD patients and healthy controls.
Number of subjects: 62
Study 33900918 — intervention group
Group type: COMPARATOR
Intervention: 3D Convolutional Neural Network (CNN) for binary classification of AUD cases.
Number of subjects: 62
Study 33067494 — intervention group
Group type: EXPERIMENTAL
Intervention: Completely randomized (CR) design
Number of subjects: 100
Study 33067494 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised block (RB) design
Number of subjects: 100
Study 33067494 — intervention group
Group type: EXPERIMENTAL
Intervention: General experimental designs
Number of subjects: 100
Study 35840886 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 Hz tACS
Number of subjects: 42
Study 35840886 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 42
Study 34938292 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy on day 1 and toripalimab on day 3 (experimental group)
Number of subjects: 30
Study 34938292 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and toripalimab on day 1 (control group)
Number of subjects: 30
Study 35284377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting cancer-specific survival (CSS) based on independent risk factors
Number of subjects: 27073
Study 35284377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting CSS
Number of subjects: 27073
Study 32726228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow
Number of subjects: 40
Study 32726228 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile flow
Number of subjects: 40
Study 34479189 — intervention group
Group type: EXPERIMENTAL
Intervention: Supercharged motor nerve transfer via a 5‐cm incision following decompression and anterior subfascial transposition
Number of subjects: 93
Study 34479189 — intervention group
Group type: COMPARATOR
Intervention: Decompression and anterior subfascial transposition alone
Number of subjects: 93
Study 33894131 — intervention group
Group type: EXPERIMENTAL
Intervention: suvratoxumab 5000 mg
Number of subjects: 213
Study 33894131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 33798730 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication coaching intervention provided by a communication coach who reviews recorded patient encounters and gives tailored feedback.
Number of subjects: 400
Study 33798730 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 400
Study 36361437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received spirometry results and smoking cessation advice)
Number of subjects: 350
Study 36361437 — intervention group
Group type: COMPARATOR
Intervention: Control group (received only smoking cessation advice)
Number of subjects: 350
Study 36361437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 350
Study 32556249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral-Based Physical Therapy (CBPT)
Number of subjects: 86
Study 32556249 — intervention group
Group type: COMPARATOR
Intervention: Education program
Number of subjects: 86
Study 35590102 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcanalicular laser dacryocystorhinostomy (TCL‐DCR) with endonasal augmentation (Group 1)
Number of subjects: 90
Study 35590102 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcanalicular laser dacryocystorhinostomy (TCL‐DCR) with endonasal augmentation after 10 days (Group 2)
Number of subjects: 90
Study 35590102 — intervention group
Group type: COMPARATOR
Intervention: External DCR (Group 3)
Number of subjects: 90
Study 35590102 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 33674821 — intervention group
Group type: EXPERIMENTAL
Intervention: Concealed opioid reduction
Number of subjects: 74
Study 33674821 — intervention group
Group type: COMPARATOR
Intervention: Standard tapering
Number of subjects: 74
Study 34853932 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aloe vera extract gel applied thrice daily for 2 months
Number of subjects: 60
Study 34853932 — intervention group
Group type: COMPARATOR
Intervention: Low-level laser therapy (LLLT) at 980 nm twice weekly for 2 months
Number of subjects: 60
Study 34810347 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidodent mouthwash
Number of subjects: 60
Study 34810347 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics mouthwash
Number of subjects: 60
Study 34810347 — intervention group
Group type: EXPERIMENTAL
Intervention: C. papaya leaf extract mouthwash
Number of subjects: 60
Study 34810347 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash (distilled water)
Number of subjects: 60
Study 35412220 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 986 tablet formulation
Number of subjects: 12
Study 35412220 — intervention group
Group type: COMPARATOR
Intervention: AMG 986 capsule formulation
Number of subjects: 12
Study 34166843 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation
Number of subjects: 414
Study 34166843 — intervention group
Group type: EXPERIMENTAL
Intervention: Early prenatal vitamin D insufficiency with late sufficiency
Number of subjects: 414
Study 34407895 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) - 40 g concentrated WP
Number of subjects: 10
Study 34407895 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysed Collagen - 40 g
Number of subjects: 10
Study 34146143 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent TBS (iTBS) to the left and continuous TBS (cTBS) to the right dlPFC
Number of subjects: 236
Study 34146143 — intervention group
Group type: COMPARATOR
Intervention: bilateral sham stimulation
Number of subjects: 236
Study 32949918 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal (HP; 30 g protein, 17 g fat, 52 g carbohydrate)
Number of subjects: 31
Study 32949918 — intervention group
Group type: COMPARATOR
Intervention: Low-protein meal (LP; 13 g protein, 25 g fat, 54 g carbohydrate)
Number of subjects: 31
Study 32949918 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal (HP)
Number of subjects: 31
Study 32949918 — intervention group
Group type: COMPARATOR
Intervention: Low-protein meal (LP)
Number of subjects: 31
Study 35980648 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized management combined with drug treatment (silver ion alginate, hydrocolloid dressing, foam dressing)
Number of subjects: 60
Study 35980648 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment (silver ion alginate, hydrocolloid dressing, foam dressing)
Number of subjects: 60
Study 34382590 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injection combined with mouth opening training for 2 years
Number of subjects: 220
Study 34382590 — intervention group
Group type: COMPARATOR
Intervention: Local injection of Salvia miltiorrhiza and triamcinolone acetonide, once a week, 8 times a course
Number of subjects: 220
Study 35764955 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg AEO BID
Number of subjects: 119